Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Tricuspid Atresia Treatment & Management

  • Author: P Syamasundar Rao, MD; Chief Editor: Howard S Weber, MD, FSCAI  more...
Updated: Jan 05, 2016

Medical Care

The prognosis for patients with tricuspid atresia and other complex congenital cardiac defects with one functioning ventricle has improved because of the advent of physiologically corrective surgery for tricuspid atresia and its modifications. However, such procedures are usually restricted to patients older than 1 year, though patients with tricuspid atresia are symptomatic in the neonatal period or early infancy. Palliation should be performed to allow infants to reach the age and weight requirements for correction.

As a consequence, the objective of any management plan is not only to provide symptomatic relief but also to preserve, protect, and restore the anatomy (with good-sized and undistorted pulmonary arteries) and physiology (normal pulmonary artery pressure and preserved left ventricular function) to normal so that a corrective procedure can be safely performed when the patient reaches an optimal age and weight.[29]

Management at presentation

Medical management during the process of identification, transfer to a pediatric cardiology center, initial workup, and cardiac catheterization (if needed) and during and after palliative surgery or procedures includes maintenance of a neutral thermal environment, normal acid-base balance, normoglycemia, and normocalcemia with appropriate monitoring and correction, if necessary.[29, 55, 72] Unless associated pulmonary parenchymal pathology is present, the fraction of inspired oxygen (FIO2) administered should be no more than 0.4.

Neonates who have low arterial PO2 and O2 saturation and ductal-dependent pulmonary blood flow should receive an intravenous infusion of PGE1 0.03-0.1 mcg/kg/min to open the ductus arteriosus or to maintain its patency.[29, 72, 73] This is followed by an aortopulmonary shunt (see Palliative surgery).

In the infant who presents with signs of congestive heart failure (type Ic or IIc), anticongestive therapy with digoxin, diuretics, and afterload reduction should be promptly given.[29, 72] Considerations pertaining to pulmonary artery banding are reviewed in Surgical Care.

In patients with severe aortic coarctation, which is particularly observed in those with type II disease, ductal dilation with an infusion of PGE1 may improve systemic perfusion.[29] Surgical repair of the coarctation should follow. Some cardiologists use balloon angioplasty to relieve the aortic obstruction.

If interatrial obstruction is present, it should be relieved by means of balloon atrial septostomy. On occasion, blade or surgical septostomy is necessary.[74, 75]

For patients presenting after infancy, the treatment approach is similar to that described above, except that PGE1 is not effective in opening the ductus.

Medical management after palliation

The management issues in tricuspid atresia are similar to those in other cyanotic congenital heart defects and are discussed in Tricuspid Atresia.[29]

Hemoglobin should be periodically measured, and anemia and polycythemia, when present, should be treated.

Patients should receive antibiotic prophylaxis before undergoing any bacteremia-producing surgery or procedures.

The risks of stroke and brain abscess are similar to those in other cyanotic heart defects. When such a problem develops, appropriate neurologic or neurosurgical consultation and treatment is indicated.[29]

Routine well-child care, including immunizations, by the primary care physician is suggested. Administration of polyvalent pneumococcal vaccine and influenza vaccine and immunization against respiratory syncytial virus should be considered.[29]

Issues such as physical and emotional development, genetic counseling, vocational training and rehabilitation,[76] pregnancy, and contraception are addressed similarly to those in other cyanotic heart defects.[77]

The development of hyperuricemia, gout, and uric acid nephropathy in adolescents and adults with long-standing cyanosis and polycythemia is similar to that in other cyanotic heart defects.[29] Timely palliative and corrective surgery may prevent such complications.

Catheter intervention

In the neonate, obstruction at the level of the atrial septum may be treated with conventional Rashkind balloon atrial septostomy.[78] In infants and children, the interatrial septum may be too thick to be torn with balloon septostomy; therefore, Park blade septostomy should precede the Rashkind procedure.[74]

In most patients, obstruction to pulmonary blood flow is at the ventricular septal defect (VSD) level or in the subpulmonary region. In some patients, though rare, the predominant obstruction is at the pulmonary valve. In such patients, balloon pulmonary valvuloplasty may be useful in improving pulmonary blood flow and oxygen saturation.[79]

If progressive cyanosis develops after a previous Blalock-Taussig shunt and if the hypoxemia is due to a stenotic shunt, balloon dilatation may be used to improve oxygen saturation.[80] Rarely, stents may be required to keep the shunt open.[81] However, if the patient is of sufficient size and age to undergo a bidirectional Glenn procedure, this procedure should be performed instead of catheter intervention to open up the narrowed Blalock-Taussig shunt.

If severe aortic coarctation is present, particularly in patients with tricuspid atresia type II, balloon angioplasty may be useful in relieving aortic obstruction and may help achieve better control of congestive heart failure.[82, 83] However, it should be mentioned that some caregivers prefer surgery to relieve the aortic obstruction.

If clinically significant branch pulmonary artery stenosis is present before bidirectional Glenn or Fontan conversion or after a Fontan procedure is performed, balloon angioplasty or placement of intravascular stents is recommended.[84, 85]

Development of aortopulmonary collateral vessels has been increasingly observed in recent studies. Before the final Fontan conversion, occlusion of these vessels in the catheterization laboratory, usually by means of coil embolization, is recommended[86, 87] to reduce left ventricular volume overloading and, probably, the duration of chest-tube drainage.

After a Fontan procedure, some patients may have recurrent pleural effusion, liver dysfunction, plastic bronchitis or protein-losing enteropathy. In these patients, rule out obstructive lesions in the Fontan circuit, then puncture of the atrial septum by using a Brockenbrough technique followed by static balloon atrial septal dilatation or stent implantation may be beneficial.

Patients who undergo a fenestrated Fontan operation or who have a residual atrial defect despite correction may have clinically significant right-to-left shunting that causes severe hypoxemia. These residual atrial defects may be closed by using transcatheter techniques.[88, 89, 90, 91]

Some patients may develop systemic venous–to–pulmonary venous collateral vessels following Fontan operation, causing arterial desaturation. These vessels should be defined and closed by coils, plugs, or devices, depending on the size, location, and accessibility.[87, 92, 93]


Surgical Care

Surgical management may be broadly grouped into palliative and corrective therapies.

Palliative surgery

Palliative therapy depends on the hemodynamic disturbance the associated cardiac anomalies produce and may be discussed in terms of decreased pulmonary flow, increased pulmonary flow, or intracardiac obstruction.[94]

Decreased pulmonary blood flow

Pulmonary blood flow may be increased by surgical creation of an aortopulmonary shunt. After Blalock and Taussig (1945) initially described subclavian artery–to–ipsilateral pulmonary artery anastomosis in 1945,[95] other procedures have been described, including Potts shunt (descending aorta–to–left pulmonary artery anastomosis), Waterston-Cooley shunt (ascending aorta–to–right pulmonary artery anastomosis), central aortopulmonary fenestration or expanded polytetrafluoroethylene (Gore-Tex; W. L. Gore & Associates, Inc, Newark, Delaware) shunt, modified Blalock-Taussig shunt (Gore-Tex interposition graft between the subclavian artery and the ipsilateral pulmonary artery), Glenn shunt (superior vena cava–to–right pulmonary artery anastomosis, end-to-end), formalin infiltration of the wall of ductus arteriosus, enlargement of the VSDs, and stent implantation into the ductus.

Modified Blalock-Taussig shunt with an interposition Gore-Tex tube graft between the subclavian artery and the ipsilateral pulmonary artery, which de Leval et al described, has stood the test of time and is currently the procedure of choice for palliation in pulmonary oligemia.[96] Some surgeons prefer central aorta to pulmonary Gore-Tex tube grafts.

Because the site of obstruction to pulmonary flow in most patients with tricuspid atresia is at the VSD, resection of the septal muscle to enlarge the VSD, which Annechino et al advocate, appears to be a logical choice because it addresses rather than bypasses the site of obstruction.[97] However, this resection is an open-heart surgical procedure and more cumbersome than the modified Blalock-Taussig shunt in augmenting the pulmonary blood flow; it has not been routinely used. In the rare patient with predominant obstruction at the pulmonary valve, balloon pulmonary valvuloplasty may be used to increase the pulmonary blood flow.[79] Stenting the arterial duct is an attractive nonsurgical option; however, because of limited experience, it is not currently a first-line therapeutic option.[98, 99]

In summary, a number of palliative procedures are available to augment pulmonary blood flow, but the modified Blalock-Taussig shunt is the recommended procedure of choice in most, if not in all, patients with tricuspid atresia with pulmonary oligemia.[29]

Increased pulmonary blood flow

Patients with increased pulmonary blood flow are likely to have type Ic or type IIc defects without associated pulmonary stenosis. Congestive heart failure is likely to occur in these patients.

In patients with tricuspid atresia type II (transposition of the great arteries), pulmonary artery banding should be performed after stabilization with anticongestive measures. Banding not only improves congestive heart failure but also helps achieve normal pulmonary artery pressure so that bidirectional Glenn and Fontan procedures can safely be performed later.[29] If associated aortic coarctation is present, it must be relieved. Pulmonary artery banding stimulates more ventricular hypertrophy, which may further reduce the size of the VSD, thus increasing subaortic obstruction.[100]

In patients with tricuspid atresia type I (normally related great arteries), aggressive anticongestive measures should promptly be undertaken. Because natural history studies suggest that the VSD spontaneously closes or becomes smaller with time and the patients with pulmonary plethora develop pulmonary oligemia, banding of the pulmonary artery is generally not recommended in this group of patients. However, if symptoms are not relieved after optimal anticongestive therapy and some delay, pulmonary-artery banding should be performed. Patients with no pulmonary-artery banding should receive careful follow-up and monitoring of pulmonary artery pressure.[29]

Absorbable pulmonary artery bands have been used for palliation in such infants.[101] By restricting the pulmonary blood flow, the absorbable polydioxanone band decreases pulmonary artery pressure and initially helps abate symptoms of heart failure. As the VSD spontaneously closes, the pulmonary artery band is resorbed and does not produce the severe pulmonary oligemia that might have been associated with a conventional nonabsorbable band. This is an ingenious approach, although it is likely to be helpful in a limited number of patients.[102]

Intracardiac obstruction

Intracardiac obstruction may occur at the level of patent foramen ovale and VSD. It can be subdivided into interatrial and interventricular obstruction.

Interatrial obstruction

Because the entire systemic venous return must pass through the patent foramen ovale, it should be large enough to allow unimpeded egress of systemic venous blood. Because of the compliant right atrium and proximal systemic veins, evaluating interatrial obstruction is difficult. Clinical signs of systemic venous congestion and presystolic hepatic and jugular venous pulsations suggest obstructed atrial septum. A mean atrial pressure difference of more than 5 mm Hg and prominent a waves in the right atrial pressure wave are generally considered diagnostic of clinically significant obstruction.[29, 33, 41]

Balloon atrial septostomy usually promptly improves presystolic hepatic and jugular pulsations and decreases interatrial pressure difference. Blade atrial septostomy is occasionally necessary, especially in older infants and children.[77, 103] Surgical atrial septostomy is needed even less frequently. However, surgical septectomy to allow unrestricted flow across the atrial system should be performed concurrently with bidirectional Glenn procedure.

Interventricular obstruction

Spontaneous closure of the VSD can occur, causing interventricular obstruction.[26, 27, 47, 49, 50, 51]

Functional VSD closure in tricuspid atresia type I results in cyanotic spells, similar to those in tetralogy of Fallot.[48] Initial management is similar to that of tetralogy of Fallot and includes knee-chest positioning, humidified oxygenation, and the administration of morphine sulfate 0.1 mg/kg. If the patient's condition is unresponsive, beta-blockers (propranolol, esmolol) or intravenous pressors (methoxamine, phenylephrine) are administered to increase systolic blood pressure by 10-20%. Concurrent correction of anemia or metabolic acidosis should also be undertaken.

If no improvement occurs, emergency surgical palliation with a Blalock-Taussig type of shunt may be necessary. If the infant's condition improves clinically, elective surgery, Blalock-Taussig shunting, or a bidirectional Glenn or Fontan procedure may be performed, depending on the patient's age and weight and the status of pulmonary arteries and left ventricle.[48]

Partial or complete anatomic closure of the VSD can also occur in patients with type I, causing pulmonary oligemia. The management is as described in the decreased pulmonary blood flow section above.

In patients with tricuspid atresia type II, spontaneous closure of the VSD produces subaortic obstruction. This obstruction should be relieved or bypassed as soon as it is detected because it produces left ventricular hypertrophy, which, in turn, increases the risk at the time of Fontan operation.[104] The VSD, right ventricle, and aortic valve may be bypassed with an anastomosis of the proximal stump of the divided pulmonary artery to the ascending aorta (Damus-Kaye-Stansel procedure) directly or by means of a prosthetic conduct at the time of bidirectional Glenn or Fontan conversion.[23, 50]

Alternatively, the conal septal muscle may be resected to enlarge the VSD[105] ; this is a direct approach in relieving the subaortic obstruction. However, development of heart block, inadequate relief of obstruction, and spontaneous closure of the surgically enlarged or created VSD remain major concerns.

Corrective surgery

After Fontan and Kreutzer's initial description of the physiologically corrective operation for tricuspid atresia,[106, 107] corrective surgery was widely adapted by most workers in the field. The concept was even extended to treat other cardiac defects with a functionally single ventricle.

The originally described Fontan operation consisted of the following[106] :

  • Superior vena cava–to–right pulmonary artery end-to-end anastomosis (Glenn procedure) [108]
  • Anastomosis of the proximal end of the divided right pulmonary artery to the right atrium directly or by means of an aortic homograft
  • Closure of the atrial septal defect (ASD)
  • Insertion of a pulmonary valve homograft into the inferior vena caval orifice
  • Ligation of the main pulmonary artery to completely bypass the right ventricle

Kreutzer performed anastomosis of the right atrial appendage and pulmonary artery directly or by using a pulmonary homograft and closed the ASD.[107] A Glenn procedure was not performed, and a prosthetic valve was not inserted into the inferior vena cava.

Fontan's concept was to use the right atrium as a pumping chamber; therefore, he inserted a prosthetic valve into the inferior vena cava and right atrial–pulmonary artery junction. Kreutzer's view was that the right atrium may not function as a pump and that the left ventricle functions as a suction pump in the system.

Numerous modifications to the aforementioned procedures were made by these and other workers in the field, as Chopra and Rao reviewed in the American Heart Journal (1992).[109] When their review was published, the 4 major types of Fontan-Kreutzer procedures used were right atrium–to–pulmonary artery anastomosis with or without a valved conduit and right atrium–to–right ventricular connection with and without a valved conduit.

Direct atriopulmonary anastomoses

On the basis of immediate-term and intermediate-term results, direct atriopulmonary anastomoses (ie, without a conduit) appears to be the best procedure for patients with type I defects who have a small (< 30% of normal) right ventricle and for all patients with type II (transposition) defects. Right atrial–to–right ventricular valved conduit (preferably homograft) anastomosis appears to be most suitable for patients with type I defects who have good-sized (>30% of normal) right ventricles and a trabecular component.[109, 110] During the time of Chopra and Rao's review, several other emerging concepts were noted, including bidirectional cavopulmonary anastomosis, fenestrated Fontan, and total cavopulmonary connection.

Bidirectional cavopulmonary anastomosis

Bidirectional cavopulmonary anastomosis is a modified Glenn procedure in which the upper end of the divided superior vena cava is anastomosed end-to-side to the right pulmonary artery without disconnecting the latter from the main pulmonary artery. Thus, the superior vena cava blood is diverted into both the right and left pulmonary arteries.

Haller et al (1996) studied experimental bidirectional cavopulmonary connection in animal models,[111] and Azzolina et al (1972) first described its clinical use.[112] Others later applied this technique to palliate complex heart defects with decreased pulmonary blood flow. Hemodynamic advantages of the bidirectional Glenn procedure are improved effective pulmonary blood flow, decreased total pulmonary blood flow, and reduced left ventricular volume overloading. Preserved continuity of the pulmonary artery is another advantage and may help enable a low-risk Fontan procedure.

When right and left superior vena cavae are present, bilateral bidirectional Glenn shunting should be performed, especially if the bridging innominate vein is absent or small.

Fenestrated Fontan operation

Fenestrated Fontan operation is another procedure used in tricuspid atresia.

Many cardiologists and surgeons have modified the criteria Choussat et al outlined.[113] Patients not meeting these criteria are at higher risk for a poor prognosis after a Fontan operation than patients who do. For the high-risk group, several workers have advanced the concept of leaving a small ASD open to facilitate decompression of the right atrium.[114, 115, 116] Laks et al advocated closure of the atrial defect by constricting the preplaced suture in the postoperative period,[116] whereas Bridges et al used a transcatheter closure technique later.[115]

Clinically significant decreases in the postoperative pleural effusions and systemic venous congestion and higher cardiac output have been noted after a fenestrated Fontan procedure. The duration of hospitalization appears to be decreased. However, these beneficial effects are at the expense of mild arterial hypoxemia.

Although the fenestrated Fontan procedure was initially conceived for patients at high risk, it has since been used in patients with modest or even low risk. Although rare, reports of cerebrovascular or other systemic arterial embolic events occurring after a fenestrated Fontan operation tend to contraindicate the use of fenestrations in patients with low or usual risk. Some data indicate that routine fenestration is not necessary.[117]

Total cavopulmonary connection

On the basis of their hemodynamic studies, de Leval et al (1988) concluded that the right atrium is not an efficient pump.[118] Flow in nonvalved circulation generates turbulence with consequent net decrease in flow, and energy losses are significant in the nonpulsatile chambers, corners, and obstructions. Using these principles, they designed and performed total cavopulmonary diversion in which the upper end of the divided superior vena cava is anastomosed end-to-side to the top of the undivided right pulmonary artery (bidirectional Glenn), and the inferior vena caval blood is routed via an intra-atrial tunnel into the cardiac end of the superior vena cava, which, in turn, is connected end-to-side to the undersurface of the right pulmonary artery.

Technical simplicity, maintenance of low right atrial and coronary sinus pressures, and reduction in right atrial thrombi are advantages of the procedure. Subsequent experimental work by Sharma et al indicated that complete or minimal offset between the orifices of the superior and inferior vena cavae into the right pulmonary artery decreases energy losses.[119]

Although the total cavopulmonary connection was initially devised for patients with complex atrial anatomy and/or systemic venous anomalies, it has since been used extensively for all types of cardiac anatomy with one functioning ventricle and irrespective of venous anomalies.

Relatively recent developments

Since the author's review more than 2 decades ago,[109, 110] several observations have been made that tended to support that total cavopulmonary connection is the Fontan procedure of choice, staged Fontan (ie, a bidirectional Glenn followed later by final conversion to Fontan) is preferred, and extracardiac conduit is preferable to lateral tunnel for diversion of inferior vena caval blood into the pulmonary artery.

However, some studies indicated equal efficacy with these 2 methods of Fontan conversion.[120]

The author originally preferred lateral tunnel Fontan conversion because creation of fenestration, if necessary, is easier to perform and the lack of growth potential for the extracardiac conduit. However, it has been observed that the creation fenestration is equally easy with extracardiac conduits.

Current surgical approaches

The patient's age, weight, and anatomic and physiologic status determine the types of surgery recommended. The overall objective is to achieve a total cavopulmonary connection.

In neonates and young infants with pulmonary oligemia, modified Blalock-Taussig shunting is undertaken to improve the pulmonary oligemia.

In patients aged 6 months to 1 year, Blalock-Taussig shunting and bidirectional Glenn procedure are the choices. The author prefers the bidirectional Glenn operation at this age. Some clinicians perform bidirectional Glenn procedures in patients as young as 3 months; however, the probability of failure is increased at this young age presumably because of pulmonary vascular reactivity.

For children aged 1-2 years, the bidirectional Glenn procedure is preferable.

For patients older than 2 years, total cavopulmonary connection may be performed, but most authorities suggest staging by using an initial bidirectional Glenn operation followed by Fontan conversion in 6-12 months.

At the time of bidirectional Glenn surgery, any narrowing of the pulmonary artery should be repaired. Issues related to subaortic obstruction and mitral valve regurgitation should also be addressed.

Before Fontan conversion, cardiac catheterization should be undertaken to ensure normal anatomy and pressure of the pulmonary artery as well as normal left ventricular end-diastolic pressure (LVEDP). At the same time, aortopulmonary collaterals should be evaluated by means of selective subclavian artery and descending thoracic aortic angiography. If collateral vessels are present, they should be occluded with coils. Some authors question routine use of pre-Fontan catheterization and suggest prospective evaluation of this issue.[121]

At the time of Fontan conversion, most surgeons currently prefer extracardiac conduit diversion of inferior vena caval blood into the right pulmonary artery. To address the growth issue related to extracardiac Fontan surgery, some surgeons use autologous[122, 123] or bovine pericardial roll grafts.[124]

In patients with associated transposition of the great arteries, early banding of the pulmonary artery, relief of aortic coarctation (if present), and bypassing (by means of a Damus-Kaye-Stansel procedure) or resecting the subaortic obstruction should be incorporated into the management plan.[29]

Emerging therapies

Two-stage cavopulmonary connection is currently recommended for achieving Fontan circulation. Konertz et al proposed a staged surgical-catheter approach.[125] They initially perform a modified hemi-Fontan that is later completed by transcatheter method.[125, 126] This approach reduces the total number of operations required.

The modified hemi-Fontan operation involves the usual bidirectional Glenn technique. The lower end of the divided superior vena cava is anastomosed to the undersurface of the right pulmonary artery. The superior vena cava is then banded around a 16-gauge catheter with 6-0 Prolene suture slightly above the cavoatrial junction. A lateral tunnel with a Gore-Tex baffle is created to divert the inferior vena caval blood toward the superior vena cava. The baffle is then fenestrated with 3-5 holes 5 mm wide. Thus, the first stage achieves a physiologic bidirectional Glenn condition.

At the time of the second stage, the transcatheter stage, the superior vena caval constriction is dilated with a balloon, and fenestrations are closed with devices or by placement of covered stent.

The original physicians[125, 126] and other workers[127, 128] have performed these procedures in a limited number of patients, and preliminary data suggest that the usual post-Fontan complications, such as pleural effusion and ascites, have not occurred with this approach. Scrutiny of results of larger experience and longer-term follow-up and ready availability of covered stents are necessary for routine application of this innovative approach.



When neurologic complications such as strokes or brain abscesses develop, consultation with neurologist or neurosurgeon is advisable for appropriate guidance of therapy.

At some time, patients may require catheter-directed therapy. Examples include balloon and/or blade atrial septostomy, static dilation of the atrial septum, balloon pulmonary valvuloplasty, balloon angioplasty of aortic coarctation, implantation of stents, coil, plug or device occlusion of collateral vessels, transcatheter closure of ASDs and/or fenestrations and creation of fenestration. Consultation with an interventional pediatric cardiologist is needed to determine the feasibility and timing of the procedures and to perform them.



In most patients with tricuspid atresia, no dietary restrictions are necessary. In patients with heart failure, fluid and salt restriction may be appropriate.

When fluid is administered by means of an intravenous and/or nasogastric route, only maintenance quantities of 100 mL/kg/day should be given. When the infant feeds independently, ad lib feedings are suggested; thirst and hunger mechanisms control intake, and the infant is unlikely to become overloaded.

Salt restriction is advised for patients with heart failure. Because food without salt is unpalatable, patients may be allowed a diet with regular salt but with a slight increase in diuretic therapy. This approach is taken in the interest of encouraging adequate caloric intake; however, adding salt to foods with a high salt content is not advised.

In infants with heart failure and failure to thrive, a high-calorie formula (24, 27, or even 30 cal/oz.) may be needed to ensure adequate weight gain. Lowered amounts of diluent (water) combined with glucose polymers (Polycose) and medium-chain triglycerides may be used.

A diet rich in medium-chain triglycerides may be useful in postoperative patients with chylothorax.




No specific exercise restrictions are recommended. Allow patients to set their own pace of activity. Participation in scholastic physical education is not discouraged, but patients may set their limits of tolerance.

Patients with tricuspid atresia, with or without corrective surgery, are not able to participate in competitive sports.

Lifestyle implications

Even after effective palliation or successful Fontan surgery, patients are left with single-ventricle physiology (ie, one functioning ventricle). These patients tolerate normal activity, but they may not be able to participate in highly exertional activities. Changes in lifestyle are necessary to avoid highly exertional activities, such as professional sports or work that requires substantial physical activity.[129]

Traveling or living at altitudes higher than 5000 feet should be undertaken carefully and with consultation and approval from the cardiologist.


Significant hemodynamic and hematologic changes occur during normal pregnancy. Cardiac output increases, initially due to an increase in stroke volume and later due to an increase in heart rate. Most of the increase takes place in the first 30 weeks' gestation, and the change is gradual.

Hematologic changes include increases in blood volume of up to 150% of pregestational values. Plasma volume is increased higher than the red cell volume with a consequent decrease in the hematocrit. Changes in regional blood flows are well documented. Uterine (and placental) blood flow increases 10-fold, and renal flow increases by 30%. Although peripheral vasodilatation occurs, the blood pressure remains constant because of increased cardiac index.

Maternal hyperventilation also occurs to meet increasing oxygen demands by the fetus. During the third trimester, the gravid uterus may compress the inferior vena cava, especially in the supine position, and decrease cardiac output.

Tolerance of cardiovascular changes

Patients with significant cyanotic heart disease poorly tolerate the pronounced cardiovascular changes. Complications include hemoptysis, pulmonary embolism, stroke, and death.

Data from patients with tricuspid atresia not operated on or palliated are sparse. The maternal mortality rate is 14%, and miscarriages occur in 54% of patients. A relatively high incidence of prematurity, small-for-gestational-age babies, and perinatal mortality have been reported.

Data are even more limited after a Fontan procedure. The limited data suggest that acceptable outcomes may result if the left ventricular function is excellent and if the functional New York Heart Association (NYHA) class is I or II at the time of conception. Further data must be obtained to make any definitive recommendations for patients who have undergone a Fontan procedure.[77]

Contributor Information and Disclosures

P Syamasundar Rao, MD Professor of Pediatrics and Medicine, Division of Cardiology, Emeritus Chief of Pediatric Cardiology, University of Texas Medical School at Houston and Children's Memorial Hermann Hospital

P Syamasundar Rao, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, American College of Cardiology, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Ameeta Martin, MD Clinical Associate Professor, Department of Pediatric Cardiology, University of Nebraska College of Medicine

Ameeta Martin, MD is a member of the following medical societies: American College of Cardiology

Disclosure: Nothing to disclose.

Chief Editor

Howard S Weber, MD, FSCAI Professor of Pediatrics, Section of Pediatric Cardiology, Pennsylvania State University College of Medicine; Director of Interventional Pediatric Cardiology, Penn State Hershey Children's Hospital

Howard S Weber, MD, FSCAI is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, Society for Cardiovascular Angiography and Interventions

Disclosure: Received income in an amount equal to or greater than $250 from: St. Jude Medical.

Additional Contributors

Paul M Seib, MD Associate Professor of Pediatrics, University of Arkansas for Medical Sciences; Medical Director, Cardiac Catheterization Laboratory, Co-Medical Director, Cardiovascular Intensive Care Unit, Arkansas Children's Hospital

Paul M Seib, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Arkansas Medical Society, International Society for Heart and Lung Transplantation, Society for Cardiovascular Angiography and Interventions

Disclosure: Nothing to disclose.

  1. Rao PS. Tricuspid atresia: anatomy, imaging, and natural history. Braunwald E, Freedom R, eds. Atlas of Heart Disease: Congenital Heart Disease. Philadelphia, PA: Current Medicine; 1997. Vol 12: 14.1.

  2. Rao PS. Tricuspid atresia. Curr Treat Options Cardiovasc Med. 2000 Dec. 2(6):507-520. [Medline].

  3. Kuhne M. Uber zwei falle kongenitaler atreside des ostium venosum dextrum. Jahrb Kinderh. 1906. 63:235.

  4. Rashkind WJ. Tricuspid atresia: a historical review. Pediatr Cardiol. 1982. 2(1):85-8. [Medline].

  5. Rao PS. Terminology: is tricuspid atresia the correct term to use?. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992: 3-15.

  6. Rao PS. Classification of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992: 59-79.

  7. Rao PS. Classification of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 41-7.

  8. Rao PS. Terminology: tricuspid atresia or univentricular heart?. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 3-6.

  9. Anderson RH, Wilkinson JL, Gerlis LM, et al. Atresia of the right atrioventricular orifice. Br Heart J. 1977 Apr. 39(4):414-28. [Medline].

  10. Bharati S, Lev M. The concept of tricuspid atresia complex as distinct from that of the single ventricle complex. Pediatr Cardiol. 1979. 1:57.

  11. Bharati S, McAllister HA Jr, Tatooles CJ, et al. Anatomic variations in underdeveloped right ventricle related to tricuspid atresia and stenosis. J Thorac Cardiovasc Surg. 1976 Sep. 72(3):383-400. [Medline].

  12. Rao PS. Is the term "tricuspid atresia" appropriate?. Am J Cardiol. 1990 Nov 15. 66(17):1251-4. [Medline].

  13. Wenink AC, Ottenkamp J. Tricuspid atresia. Microscopic findings in relation to "absence" of the atrioventricular connexion. Int J Cardiol. 1987 Jul. 16(1):57-73. [Medline].

  14. Gessner IH. Embryology of atrioventricular valve formation and embryogenesis of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992: 25-40.

  15. Ando M, Santomi G, Takao A. Atresia of tricuspid and mitral orifice: anatomic spectrum and morphogenetic hypothesis. Van Praagh R, Takao A, eds. Etiology and Morphogenesis of Congenital Heart Disease. NY: Futura: Mount Kisco; 1980: 421-87.

  16. Van Mierop LH, Gessner IH. Pathogenetic mechanisms in congenital cardiovascular malformations. Prog Cardiovasc Dis. 1972 Jul-Aug. 15(1):67-85. [Medline].

  17. Wilson AD, Rao PS. Embryology. Kambam J, ed. Cardiac Anesthesia for Infants and Children. St Louis, Mo: Mosby; 1994. 3-9.

  18. Rao PS. Tricuspid atresia. Long WA, ed. Fetal and Neonatal Cardiology. Philadelphia, Pa: WB Saunders; 1990. 525-40.

  19. Keefe JF, Wolk MJ, Levine HJ. Isolated tricuspid valvular stenosis. Am J Cardiol. 1970 Feb. 25(2):252-7. [Medline].

  20. Van Praagh R, Ando M, Dungan WT. Anatomic types of tricuspid atresia: clinical and developmental implications [abstract]. Circulation. 1971. 44:115.

  21. Rao PS, Jue KL, Isabel-Jones J, Ruttenberg HD. Ebstein's malformation of the tricuspid valve with atresia. Differentiation from isolated tricuspid atresia. Am J Cardiol. 1973 Dec. 32(7):1004-9. [Medline].

  22. Scalia D, Russo P, Anderson RH, et al. The surgical anatomy of hearts with no direct communication between the right atrium and the ventricular mass--so-called tricuspid atresia. J Thorac Cardiovasc Surg. 1984 May. 87(5):743-55. [Medline].

  23. Rao PS. Natural history of ventricular septal defects in tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 32(7): 261-93.

  24. Weinberg PM. Anatomy of tricuspid atresia and its relevance to current forms of surgical therapy. Ann Thorac Surg. 1980 Apr. 29(4):306-11. [Medline].

  25. Weinberg PM. Pathologic anatomy of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Futura: Mount Kisco, NY; 1992. 49-67.

  26. Rao PS. Natural history of the ventricular septal defect in tricuspid atresia and its surgical implications. Br Heart J. 1977 Mar. 39(3):276-88. [Medline]. [Full Text].

  27. Rao PS. Physiologically advantageous ventricular septal defects. Pediatr Cardiol. 1983 Jan-Mar. 4(1):59-61. [Medline].

  28. Ottenkamp J, Wenink AC, Quaegebeur JM, et al. Tricuspid atresia. Morphology of the outlet chamber with special emphasis on surgical implications. J Thorac Cardiovasc Surg. 1985 Apr. 89(4):597-603. [Medline].

  29. Rao PS, Covitz W, Chopra PS. Principles of palliative management of patients with tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 4(1): 297-320.

  30. Rao PS, Levy JM, Nikicicz E, Gilbert-Barness EF. Tricuspid atresia: association with persistent truncus arteriosus. Am Heart J. 1991 Sep. 122(3 Pt 1):829-35. [Medline].

  31. Van Praagh R. Discussion after paper by Vlad P: Pulmonary atresia with intact ventricular septum. Barrett-Boyes BG, Neutze JM, Harris EA, eds. Heart Disease in Infancy: Diagnosis and Surgical Treatment. 2nd ed. London: Churchill Livingstone; 1992. 1973:236.

  32. Astley R, Oldham JS, Parsons C. Congenital tricuspid atresia. Br Heart J. 1953 Jul. 15(3):287-97. [Medline]. [Full Text].

  33. Dick M, Fyler DC, Nadas AS. Tricuspid atresia: clinical course in 101 patients. Am J Cardiol. 1975 Sep. 36(3):327-37. [Medline].

  34. Edwards JE, Burchell HB. Congenital tricuspid atresia: a classification. Med Clin North Am. 1949. 33:1117.

  35. Keith J, Rowe RD, Vlad P. Heart Disease in Infancy and Childhood. Tricuspid Atresia. 2nd ed. New York: Macmillian; 1967. 434: 664.

  36. Vlad P. Tricuspid atresia. Keith JD, Rowe RD, Vlad P, eds. Heart Disease in Infancy and Childhood. 3rd ed. New York: Macmillian; 1977. 518-41.

  37. Rao PS. A unified classification for tricuspid atresia. Am Heart J. 1980 Jun. 99(6):799-804. [Medline].

  38. Rudolph AM. Tricuspid atresia with hypoplastic right ventricle. Congenital Disease of the Heart. Chicago, Ill: Year Book Medical; 1974. 429-61.

  39. Rao PS. Perinatal circulatory physiology. Indian J Pediatr. 1991 Jul-Aug. 58(4):441-51. [Medline].

  40. Rao PS. Tricuspid atresia. Moller JH, Hoffman JIE, eds. Pediatric Cardiovascular Medicine. New York: Churchill Livingstone; 2000. 43(3): 421-41.

  41. Dick M, Rosenthal A. The clinical profile of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. NY: Futura: Mount Kisco; 1982. 83-111.

  42. Rosenthal A, Dick M, II. Tricuspid atresia. Adams FH, Emmanouilides GC, eds. Moss' Heart Disease in Infants, Children, and Adolescents. 3rd ed. Baltimore, Md: Lippincott Williams & Wilkins; 1983. 271.

  43. La Corte MA, Dick M, Scheer G, La Farge CG, Fyler DC. Left ventricular function in tricuspid atresia. Angiographic analysis in 28 patients. Circulation. 1975 Dec. 52(6):996-1000. [Medline].

  44. Graham TP Jr, Erath HG Jr, Boucek RJ Jr, Boerth RC. Left ventricular function in cyanotic congenital heart disease. Am J Cardiol. 1980 Jun. 45(6):1231-6. [Medline].

  45. Rao PS, Alpert BS, Covitz W. Left ventricular function in tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 52(6): 247-59.

  46. Tzifa A, Gauvreau K, Geggel RL. Factors associated with development of atrial septal restriction in patients with tricuspid atresia involving the right-sided atrioventricular valve. Am Heart J. 2007 Dec. 154(6):1235-41. [Medline].

  47. Rao PS, Sissman NJ. Spontaneous closure of physiologically advantageous ventricular septal defects. Circulation. 1971 Jan. 43(1):83-90. [Medline].

  48. Rao PS, Linde LM, Liebman J, Perrin E. Functional closure of physiologically advantageous ventricular septal defects. Observations in three cases with tricuspid atresia. Am J Dis Child. 1974 Jan. 127(1):36-40. [Medline].

  49. Gallaher ME, Fyler DC. Observations on changing hemodynamics in tricuspid atresia without associated transposition of the great vessels. Circulation. 1967 Feb. 35(2):381-8. [Medline].

  50. Rao PS. Further observations on the spontaneous closure of physiologically advantageous ventricular septal defects in tricuspid atresia: surgical implications. Ann Thorac Surg. 1983 Feb. 35(2):121-31. [Medline].

  51. Sauer U, Hall D. Spontaneous closure or critical decrease in size of the ventricular septal defect in tricuspid atresia with normally connected great arteries: surgical implications. 1980. 5:369.

  52. Bloomfield DK. The Natural History of Ventricular Septal Defect in Patients Surviving Infancy. Circulation. 1964 Jun. 29:914-55. [Medline].

  53. Hoffman JI, Rudolph AM. The natural history of ventricular septal defects in infancy. Am J Cardiol. 1965 Nov. 16(5):634-53. [Medline].

  54. Rao PS. Demographic features of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 23-37.

  55. Rao PS. Management of neonate with suspected serious heart disease. King Faisal Spec Hosp Med J. 1984. (4):209.

  56. Marcelletti CF, Hanley FL, Mavroudis C, et al. Revision of previous Fontan connections to total extracardiac cavopulmonary anastomosis: A multicenter experience. J Thorac Cardiovasc Surg. 2000 Feb. 119(2):340-6. [Medline].

  57. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births. Incidence and natural history. Circulation. 1971 Mar. 43(3):323-32. [Medline].

  58. Schriere V. Experience with congenital heart defects at Groote Schuur Hospital, Cape Town. South Afr Med J. 1963. 37:1175.

  59. Marcano BA, Riemenschneider TA, Ruttenberg HD, Goldberg SJ, Gyepes M. Tricuspid atresia with increased pulmonary blood flow. An analysis of 13 cases. Circulation. 1969 Sep. 40(3):399-410. [Medline].

  60. Rao PS. Pathophysiologic consequences of cyanotic congenital heart disease. Indian J Pediatr. Sep-Oct 1983. 50(406):479-87.

  61. Covitz W, Rao PS. Non-invasive evaluation of patients with tricuspid atresia (roentgenography, echocardiography and nuclear angiography). Rao PS, ed. Tricuspid Atresia. 2nd ed. NY: Futura: Mount Kisco; 1992: 165-82.

  62. Gamboa R, Gersony WM, Nadas AS. The electrocardiogram in tricuspid atresia and pulmonary atresia with intact ventricular septum. Circulation. 1966 Jul. 34(1):24-37. [Medline].

  63. Rao PS, Kulungara RJ, Boineau JP. Electrovectorcardiographic features of tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 141-64.

  64. Rao PS. Cardiac catheterization in tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 153-78.

  65. Rao PS. Cardiac catheterization in tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, New York: Futura; 1992: 193-221.

  66. Rao PS. The femoral route for cardiac catheterization of infants and children. Chest. 1973 Feb. 63(2):239-41. [Medline].

  67. Rao PS. Left to right atrial shunting in tricuspid atresia. Br Heart J. 1983 Apr. 49(4):345-9. [Medline].

  68. Rao PS, Sissman NJ. The relationship of pulmonary venous wedge to pulmonary arterial pressures. Circulation. 1971 Oct. 44(4):565-74. [Medline].

  69. Mair DD, Hagler DJ, Puga FJ, Schaff HV, Danielson GK. Fontan operation in 176 patients with tricuspid atresia. Results and a proposed new index for patient selection. Circulation. 1990 Nov. 82(5 Suppl):IV164-9. [Medline].

  70. Schwartz DC, Rao PS. Angiography in tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. NY: Futura: Mount Kisco; 1992. 1(3): 223-46.

  71. Rao PS. Value of pulmonary vein wedge angiography in visualization of obstructed ipsilateral pulmonary artery. Cardiovasc Radiol. 1978 Jul 25. 1(3):151-2. [Medline].

  72. Rao PS. Principles of management of the neonate with congenital heart disease neonatology Today. 2007. 2(8):1-10.

  73. Freed MD, Heymann MA, Lewis AB, Roehl SL, Kensey RC. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease. Circulation. 1981 Nov. 64(5):899-905. [Medline].

  74. Rao PS. Transcatheter blade atrial septostomy. Cathet Cardiovasc Diagn. 1984. 10(4):335-42. [Medline].

  75. Rao PS. Role of interventional cardiology in neonates: Part I. Non-surgical atrial septostomy. Congenital Cardiol Today. 2007. 5(12):1-12,.

  76. Lichtman SW, Caravano M, Schneyman M, Howell B, King ML. Successful outpatient cardiac rehabilitation in an adult patient post-surgical repair for tricuspid valve atresia and hypoplastic right ventricle: a case study. J Cardiopulm Rehabil Prev. 2008 Jan-Feb. 28(1):48-51. [Medline].

  77. Strong WB, Morera JA, Rao PS. Sexuality, contraception and pregancy in patients with cyanotic congenital heart disease with special reference to tricuspid atresia. Rao PS, ed. Tricuspid Atresia. 2nd ed. NY: Futura: Mount Kisco; 1992. 16(1): 415-27.

  78. Rashkind W, Waldhausen J, Miller W, Friedman S. Palliative treatment in tricuspid atresia. Combined balloon atrioseptostomy and surgical alteration of pulmonary blood flow. J Thorac Cardiovasc Surg. 1969 Jun. 57(6):812-8. [Medline].

  79. McCredie RM, Swinburn MJ, Lee CL, Warner G. Balloon dilatation pulmonary valvuloplasty in pulmonary stenosis. Aust N Z J Med. 1986 Feb. 16(1):20-3. [Medline].

  80. Rao PS, Levy JM, Chopra PS. Balloon angioplasty of stenosed Blalock-Taussig anastomosis: role of balloon-on-a-wire in dilating occluded shunts. Am Heart J. 1990 Nov. 120(5):1173-8. [Medline].

  81. Tsounias E, Rao PS. Stent therapy for clotted Blalock-Taussig shunts. Congenital Cardiol Today. 2010. 8(7):1-9.

  82. Rao PS. Current status of balloon angioplasty for neonatal and infant aortic coarctation. Progress Pediat Cardiol. 2001. 14:35-44.

  83. Rao PS, Jureidini SB, Balfour IC, Singh GK, Chen S. Severe aortic coarctation in infants less than 3 months: Successful palliation by balloon angioplasty. J Invasive Cardiol. 2003. 15:203-208.

  84. Rao PS, Balfour IC, Singh GK, Jureidini SB, Chen S. Bridge stents in the management of obstructive vascular lesions in children. Am J Cardiol. 2001. 88:699-702.

  85. Rao PS. Stents in the management of congenital heart disease in pediatric and adult patients. Indian Heart J. 2001 Nov-Dec. 53(6):714-30. [Medline].

  86. Siblini G, Rao PS. Coil Embolization in the Management of Cardiac Problems in Children. J Invasive Cardiol. 1996. 8:332-40.

  87. Rao PS. Transcatheter embolization of unwanted blood vessels in children. Rao PS, Kern MJ. (editors). Catheter Based Devices for Treatment of Noncoronary Cardiovascular Disease in Adults and Children. Philadelphia, PA: Lippincott, Williams & Wilkins; 2003. 251(16): 2123-38.

  88. Rao PS, Chandar JS, Sideris EB. Role of inverted buttoned device in transcatheter occlusion of atrial septal defects or patent foramen ovale with right-to-left shunting associated with previously operated complex congenital cardiac anomalies. Am J Cardiol. 1997 Oct 1. 80(7):914-21. [Medline].

  89. Goff DA, Blume ED, Gauvreau K, Mayer JE, Lock JE, Jenkins KJ. Clinical outcome of fenestrated Fontan patients after closure: the first 10 years. Circulation. 2000 Oct 24. 102(17):2094-9. [Medline].

  90. Boudjemline Y, Bonnet D, Sidi D, Agnoletti G. [Closure of extrocardiac Fontan fenestration by using the Amplatzer duct occluder]. Arch Mal Coeur Vaiss. 2005 May. 98(5):449-54. [Medline].

  91. Rothman A, Evans WN, Mayman GA. Percutaneous fenestration closure with problematic residual native atrial septum. Catheter Cardiovasc Interv. 2005 Oct. 66(2):286-90. [Medline].

  92. Sugiyama H, Yoo SJ, Williams W, Benson LN. Characterization and treatment of systemic venous to pulmonary venous collaterals seen after the Fontan operation. Cardiol Young. 2003 Oct. 13(5):424-30. [Medline].

  93. Tsounias E, Rao PS. Versatility of Amplatzer Vascular Plug in occlusion of different types of vascular channels. Cathet Cardivas Intevent. 2008.

  94. Alsoufi B, Schlosser B, Mori M, et al. Influence of Morphology and Initial Surgical Strategy on Survival of Infants With Tricuspid Atresia. Ann Thorac Surg. 2015 Oct. 100 (4):1403-9; discussion 1409-10. [Medline].

  95. Blalock A, Taussig HB. Landmark article May 19, 1945: The surgical treatment of malformations of the heart in which there is pulmonary stenosis or pulmonary atresia. By Alfred Blalock and Helen B. Taussig. JAMA. 1984 Apr 27. 251(16):2123-38. [Medline].

  96. de Leval MR, McKay R, Jones M, Stark J, Macartney FJ. Modified Blalock-Taussig shunt. Use of subclavian artery orifice as flow regulator in prosthetic systemic-pulmonary artery shunts. J Thorac Cardiovasc Surg. 1981 Jan. 81(1):112-9. [Medline].

  97. Annecchino FP, Fontan F, Chauve A, Quaegebeur J. Palliative reconstruction of the right ventricular outflow tract in tricuspid atresia: a report of 5 patients. Ann Thorac Surg. 1980 Apr. 29(4):317-21. [Medline].

  98. Gibbs JL, Rothman MT, Rees MR, Parsons JM, Blackburn ME, Ruiz CE. Stenting of the arterial duct: a new approach to palliation for pulmonary atresia. Br Heart J. 1992 Mar. 67(3):240-5. [Medline]. [Full Text].

  99. Alwi M, Choo KK, Latiff HA, Kandavello G, Samion H, Mulyadi MD. Initial results and medium-term follow-up of stent implantation of patent ductus arteriosus in duct-dependent pulmonary circulation. J Am Coll Cardiol. 2004 Jul 21. 44(2):438-45. [Medline].

  100. Rao PS. Subaortic obstruction after pulmonary artery banding in patients with tricuspid atresia and double-inlet left ventricle and ventriculoarterial discordance. J Am Coll Cardiol. 1991 Nov 15. 18(6):1585-6. [Medline].

  101. Bonnet D, Sidi D, Vouhe PR. Absorbable pulmonary artery banding in tricuspid atresia. Ann Thorac Surg. 2001 Jan. 71(1):360-1; discussion 361-2. [Medline].

  102. Rao PS. Absorbable pulmonary artery band in tricuspid atresia (Editorial). Ann Thorac Surg. 2001. 71:361-362.

  103. Park SC, Neches WH, Zuberbuhler JR, et al. Clinical use of blade atrial septostomy. Circulation. 1978 Oct. 58(4):600-6. [Medline].

  104. Seliem M, Muster AJ, Paul MH, Benson DW Jr. Relation between preoperative left ventricular muscle mass and outcome of the Fontan procedure in patients with tricuspid atresia. J Am Coll Cardiol. 1989 Sep. 14(3):750-5. [Medline].

  105. Smolinsky A, Castaneda AR, Van Praagh R. Infundibular septal resection: surgical anatomy of the superior approach. J Thorac Cardiovasc Surg. 1988 Mar. 95(3):486-94. [Medline].

  106. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971 May. 26(3):240-8. [Medline]. [Full Text].

  107. Kreutzer G, Bono H, Galindez E. Una operacion para la correccion de la atresia tricuspidea. Ninth Argent Congress of Cardiology; Buenos Aires, Argentina. October 31-November 6, 1971;.

  108. Glenn WW. Circulatory bypass of the right side of the heart. IV. Shunt between superior vena cava and distal right pulmonary artery; report of clinical application. N Engl J Med. 1958 Jul 17. 259(3):117-20. [Medline].

  109. Chopra PS, Rao PS. Corrective surgery for tricuspid atresia: which modification of Fontan-Kreutzer procedure should be used? A review. Am Heart J. 1992 Mar. 123(3):758-67. [Medline].

  110. Rao PS, Chopra PS. Modifications of Fontan-Kreutzer procedure for tricuspid atresia: can a choice be made?. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, New York: Futura; 1992. 34(2): 361-75.

  111. Haller JA Jr, Adkins JC, Worthington M, Rauenhorst J. Experimental studies on permanent bypass of the right heart. Surgery. 1966 Jun. 59(6):1128-32. [Medline].

  112. Azzolina G, Eufrate S, Pensa P. Tricuspid atresia: experience in surgical management with a modified cavopulmonary anastomosis. Thorax. 1972 Jan. 27(1):111-5. [Medline]. [Full Text].

  113. Choussat A, Fontan F, Besse P, et al. Selection criteria for Fontan procedure. Anderson RH, Shinebourne EA, eds. Pediatric Cardiology. White Plains, NY: Churchill Livingstone; 1978. 559.

  114. Billingsley AM, Laks H, Boyce SW, George B, Santulli T, Williams RG. Definitive repair in patients with pulmonary atresia and intact ventricular septum. J Thorac Cardiovasc Surg. 1989 May. 97(5):746-54. [Medline].

  115. Bridges ND, Lock JE, Castaneda AR. Baffle fenestration with subsequent transcatheter closure. Modification of the Fontan operation for patients at increased risk. Circulation. 1990 Nov. 82(5):1681-9. [Medline].

  116. Laks H, Pearl JM, Haas GS, et al. Partial Fontan: advantages of an adjustable interatrial communication. Ann Thorac Surg. 1991 Nov. 52(5):1084-94; discussion 1094-5. [Medline].

  117. Thompson LD, Petrossian E, McElhinney DB, et al. Is it necessary to routinely fenestrate an extracardiac fontan?. J Am Coll Cardiol. 1999 Aug. 34(2):539-44. [Medline].

  118. de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J Thorac Cardiovasc Surg. 1988 Nov. 96(5):682-95. [Medline].

  119. Sharma S, Goudy S, Walker P, et al. In vitro flow experiments for determination of optimal geometry of total cavopulmonary connection for surgical repair of children with functional single ventricle. J Am Coll Cardiol. 1996 Apr. 27(5):1264-9. [Medline].

  120. Kumar SP, Rubinstein CS, Simsic JM, Taylor AB, Saul JP, Bradley SM. Lateral tunnel versus extracardiac conduit Fontan procedure: a concurrent comparison. Ann Thorac Surg. 2003 Nov. 76(5):1389-96; discussion 1396-7. [Medline].

  121. Ro PS, Rychik J, Cohen MS, Mahle WT, Rome JJ. Diagnostic assessment before Fontan operation in patients with bidirectional cavopulmonary anastomosis: are noninvasive methods sufficient?. J Am Coll Cardiol. 2004 Jul 7. 44(1):184-7. [Medline].

  122. Adachi I, Yagihara T, Kagisaki K, et al. Fontan operation with a viable and growing conduit using pedicled autologous pericardial roll: serial changes in conduit geometry. J Thorac Cardiovasc Surg. 2005 Dec. 130(6):1517-22. [Medline].

  123. Yalcinbas YK, Erek E, Salihoglu E, Sarioglu A, Sarioglu T. Early results of extracardiac fontan procedure with autologous pericardial tube conduit. Thorac Cardiovasc Surg. 2005 Feb. 53(1):37-40. [Medline].

  124. Lemler MS, Ramaciotti C, Stromberg D, Scott WA, Leonard SR. The extracardiac lateral tunnel Fontan, constructed with bovine pericardium: comparison with the extracardiac conduit Fontan. Am Heart J. 2006 Apr. 151(4):928-33. [Medline].

  125. Konertz W, Schneider M, Herwig V, Kampmann C, Waldenberger F, Hausdorf G. Modified hemi-Fontan operation and subsequent nonsurgical Fontan completion. J Thorac Cardiovasc Surg. 1995 Sep. 110(3):865-7. [Medline].

  126. Hausdorf G, Schneider M, Konertz W. Surgical preconditioning and completion of total cavopulmonary connection by interventional cardiac catheterisation: a new concept. Heart. 1996 Apr. 75(4):403-9. [Medline]. [Full Text].

  127. Sidiropoulos A, Ritter J, Schneider M, Konertz W. Fontan modification for subsequent non-surgical Fontan completion. Eur J Cardiothorac Surg. 1998 May. 13(5):509-12; discussion 512-3. [Medline].

  128. Galantowicz M, Cheatham JP. Fontan completion without surgery. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004. 7:48-55. [Medline].

  129. van den Bosch AE, Roos-Hesselink JW, Van Domburg R, Bogers AJ, Simoons ML, Meijboom FJ. Long-term outcome and quality of life in adult patients after the Fontan operation. Am J Cardiol. 2004 May 1. 93(9):1141-5. [Medline].

  130. Freedom RM, et al. The Fontan procedure for patients with tricuspid atresia: long-term follow-up. Rao PS, ed. Tricuspid Atresia. 2nd ed. Mount Kisco, NY: Futura; 1992. 128(1): 377.

  131. Stamm C, Friehs I, Mayer JE Jr, et al. Long-term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg. 2001 Jan. 121(1):28-41. [Medline].

  132. Lubiszewska B, Rozanski J, Demkow M, et al. Long-term results of Fontan procedure in 43 patients. Kardiol Pol. 2003 Mar. 58(3):207-16. [Medline].

  133. Alphonso N, Baghai M, Sundar P, Tulloh R, Austin C, Anderson D. Intermediate-term outcome following the fontan operation: a survival, functional and risk-factor analysis. Eur J Cardiothorac Surg. 2005 Oct. 28(4):529-35. [Medline].

  134. Mitchell ME, Ittenbach RF, Gaynor JW, Wernovsky G, Nicolson S, Spray TL. Intermediate outcomes after the Fontan procedure in the current era. J Thorac Cardiovasc Surg. 2006 Jan. 131(1):172-80. [Medline].

  135. McCrindle BW, Williams RV, Mitchell PD, et al. Relationship of patient and medical characteristics to health status in children and adolescents after the Fontan procedure. Circulation. 2006 Feb 28. 113(8):1123-9. [Medline].

  136. Sheikh AM, Tang AT, Roman K, et al. The failing Fontan circulation: successful conversion of atriopulmonary connections. J Thorac Cardiovasc Surg. 2004 Jul. 128(1):60-6. [Medline].

  137. Hill DJ, Feldt RH, Porter C. Protein losing enteropathy after Fontan operation: a preliminary report. Circulation. 1989. 80(Suppl II):490.

  138. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg. 1998 May. 115(5):1063-73. [Medline].

  139. Rao PS. Protein-losing enteropathy following the Fontan operation. J Invasive Cardiol. 2007 Oct. 19(10):447-8. [Medline].

  140. Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 1996 Sep. 112(3):672-80. [Medline].

  141. Giannico S, Hammad F, Amodeo A, et al. Clinical outcome of 193 extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol. 2006 May 16. 47(10):2065-73. [Medline].

  142. Chiu NT, Lee BF, Hwang SJ, Chang JM, Liu GC, Yu HS. Protein-losing enteropathy: diagnosis with (99m)Tc-labeled human serum albumin scintigraphy. Radiology. 2001 Apr. 219(1):86-90. [Medline].

  143. Masetti P, Marianeschi SM, Cipriani A, Iorio FS, Marcelletti CF. Reversal of protein-losing enteropathy after ligation of systemic-pulmonary shunt. Ann Thorac Surg. 1999 Jan. 67(1):235-6. [Medline].

  144. Zellers TM, Brown K. Protein-losing enteropathy after the modified fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol. 1996 Mar-Apr. 17(2):115-7. [Medline].

  145. Therrien J, Webb GD, Gatzoulis MA. Reversal of protein losing enteropathy with prednisone in adults with modified fontan operations: long term palliation or bridge to cardiac transplantation?. Heart. 1999 Aug. 82(2):241-3. [Medline]. [Full Text].

  146. Guariso G, Cerutti A, Moreolo GS, Milanesi O. Protein-losing enteropathy after fontan operation: treatment with elementary diet in one case. Pediatr Cardiol. 2000 May-Jun. 21(3):292. [Medline].

  147. Kim SJ, Park IS, Song JY, Lee JY, Shim WS. Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation. Ann Thorac Surg. 2004 Apr. 77(4):1456-7. [Medline].

  148. Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr. 1997 Mar. 130(3):474-8. [Medline].

  149. Kelly AM, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease. Mayo Clin Proc. 1998 Aug. 73(8):777-9. [Medline].

  150. Facchini M, Guldenschuh I, Turina J, Jenni R, Schalcher C, Attenhofer Jost CH. Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia. J Cardiovasc Surg (Torino). 2000 Aug. 41(4):567-70. [Medline].

  151. Ringel RE, Peddy SB. Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol. 2003 Apr 15. 91(8):1031-2, A9. [Medline].

  152. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg. 2006 Dec. 82(6):e39-40. [Medline].

  153. Connor FL, Angelides S, Gibson M, et al. Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium-dextran scintigraphy. Pediatrics. 2003 Sep. 112(3 Pt 1):e242-7. [Medline].

  154. Mertens L, Dumoulin M, Gewillig M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Br Heart J. 1994 Dec. 72(6):591-2. [Medline]. [Full Text].

  155. Lemes V, Murphy AM, Osterman FA, Laschinger JC, Kan JS. Fenestration of extracardiac fontan and reversal of protein-losing enteropathy: case report. Pediatr Cardiol. 1998 Jul-Aug. 19(4):355-7. [Medline].

  156. Fraisse A, Bonnet JL. Protein-losing enteropathy: radiofrequency fenestration of the atrial septum after failure of transseptal needle puncture. Pediatr Cardiol. 2004 Jan-Feb. 25(1):84-6. [Medline].

  157. Kreutzer J, Keane JF, Lock JE, et al. Conversion of modified Fontan procedure to lateral tunnel cavopulmonary anastomosis. J Thorac Cardiovasc Surg. 1997. 1169-117.

  158. Brancaccio G, Carotti A, D'Argenio P, Michielon G, Parisi F. Protein-losing enteropathy after Fontan surgery: resolution after cardiac transplantation. J Heart Lung Transplant. 2003 Apr. 22(4):484-6. [Medline].

  159. Estner HL, Kolb C, Schmitt C, et al. Long-term transvenous AV-sequential pacing in a failing atriopulmonary Fontan patient. Int J Cardiol. 2008 Jul 4. 127(2):e93-5. [Medline].

  160. Lopez JA. Transvenous right atrial and left ventricular pacing after the Fontan operation: long-term hemodynamic and electrophysiologic benefit of early atrioventricular resynchronization. Texas Heart Institut. 2007. 34(1):96-101.

  161. Gamba A, Merlo M, Fiocchi R, et al. Heart transplantation in patients with previous Fontan operations. J Thorac Cardiovasc Surg. 2004 Feb. 127(2):555-62. [Medline].

  162. Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol. 2004 Nov 16. 44(10):2065-72. [Medline].

  163. Petko M, Myung RJ, Wernovsky G, et al. Surgical reinterventions following the Fontan procedure. Eur J Cardiothorac Surg. 2003 Aug. 24(2):255-9. [Medline].

Cardiac specimen from a patient with the muscular type of tricuspid atresia. The right atrium was opened by cutting through the right atrial appendage (RAA). Note the dimple (arrow) in the floor of the right atrium with muscle fibers radiating around it. An atrial septal defect (ASD) is also shown. From Rao PS, Levy JM, Nikicicz E, Gilbert-Barness EF. Tricuspid atresia: association with persistent truncus arteriosus. Am Heart J 1991, 122:829, with permission.
Systemic arterial saturations. Left ventricular (LV) and aortic (Ao) values are plotted against the pulmonary-to-systemic blood-flow ratio (Qp:Qs). Both type I and type II anatomy are included. Note the curvilinear relationship between the parameters. At low Qp:Qs levels, a slight increase in Qp:Qs produces large increase in systemic oxygen saturation; at high Qp:Qs levels, a further increase does not produce a notable increase in oxygen saturation. The ideal Qp:Qs appears to be 1.5-2.5, which results in oxygen saturations in the low 80s. From Rao PS. Cardiac catheterization in tricuspid atresia. In: Rao PS, ed. Tricuspid Atresia. 2nd ed. Mt Kisco, NY: Futura Publishing Co: 1982:153, with permission.
Geographic prevalence of tricuspid atresia by continent. Note that prevalences are similar on all continents except for Australia. This lone exception is thought to be related to the small sample size from Australia. CHD = congenital heart defects; TA = tricuspid atresia. From Rao PS. Demographic features of tricuspid atresia. In: Rao PS, ed, Tricuspid Atresia. 2nd ed. Mt Kisco, NY: Futura Publishing Co; 1992:23, with permission.
Actuarial survival curves from 3 reported clinical series compiled by Dick and Rosenthal (1992) show a high initial mortality rate in the first year of life, a plateau between the first year and middle of the second decade of life, and a second increase in the mortality rate after the middle of the second decade of life; this second rise is presumably related to impaired left ventricular function. From Dick M and Rosenthal A. The clinical profile of tricuspid atresia. In: Rao PS, ed. Tricuspid Atresia. Mt Kisco, NY: Futura Publishing Co; 1982:83, with permission.
Actuarial survival rate of 100 patients who had tricuspid atresia and who were undergoing a Fontan operation at the Hospital for Sick Children, Toronto, in 1975-1989. The survival rate 5 years after the operation is 70%. From Freedom RM, et al. The Fontan procedure for patients with tricuspid atresia: long-term follow-up. In: Rao PS, ed. Tricuspid Atresia. 2nd ed. Mt Kisco, NY: Futura Publishing Co; 1992:377, with permission.
Use of electrocardiographic mean QRS vector (axis) in the frontal plane for the differential diagnosis of a cyanotic newborn with decreased pulmonary blood flow. Associated ventricular hypertrophy patterns and decreased right ventricular (RV) forces are also helpful. From Rao PS. Management of neonate with suspected serious heart disease. King Faisal Spec Hosp Med J 1984 (4):209, with permission.
Frontal plane mean QRS vector in 308 patients, plotted by anatomic type. Most patients with tricuspid atresia type I (normally related great arteries) have an abnormally superior vector, also called left axis deviation. Only one half of patients with tricuspid atresia type II have an abnormally superior vector. Most patients with tricuspid atresia type III (subtype A) have an inferiorly oriented frontal plane vector. From Rao PS, Kulungara RJ, Boineau JP. Electrovectorcardiographic features of tricuspid atresia. In: Rao PS, ed, Tricuspid Atresia. 2nd ed. Mt Kisco, NY: Futura Publishing Co; 1992:141, with permission.
Subcostal 4-chamber 2-dimensional echocardiographic view of a neonate with tricuspid atresia shows an enlarged left ventricle (LV), a small right ventricle (RV), and a dense band of echoes where the tricuspid valve echo should be. Atrial and ventricular septal defects and the mitral valve are also seen. Note the attachment of the anterior leaflet of the detectable atrioventricular valve to the left side of the interatrial septum. Reprinted from Rao, Fetal and Neonatal Cardiology, 1990, with permission from Elsevier Science.
Selected cineangiographic frames from superior vena caval (SVC) and right atrial (RA) frontal angiography in 2 patients. Note sequential opacification of the left atrium (LA) and left ventricle (LV) without opacification of the right ventricle. The RA on the right, the LA superiorly, and the LV on the left form a nonopacified right ventricular window (arrow). This is a classic appearance of the muscular variety of tricuspid atresia. From Rao PS. Tricuspid atresia: anatomy, imaging, and natural history. In: Brawnwald E, Freedom RM, eds. Atlas of Heart Disease: Congenital Heart Disease. Vol 12. Philadelphia, PA: Current Medicine; 1997:14.1 with permission.
Selective superior vena caval (SVC) injection for a 4-chamber projection (hepatoclavicular) shows tricuspid atresia and filling of the left atrium (LA) through a somewhat restrictive atrial septal defect (arrows). Note the retrograde filling of the coronary sinus (CS). RA = right atrium. From Schwartz DC, Rao PS. Angiography in tricuspid atresia. In: Rao PS, ed. Tricuspid Atresia. 2nd ed. Mt Kisco, NY: Futura Publishing Co; 1992:223, with permission.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.